Targeting T and B lymphocytes in inflammatory bowel diseases: Lessons from clinical trials

Digestive Diseases

Volumn 31, Issue 3-4, 2013, Pages 328-335

  Gerner, R R ^a   Moschen, A R ^a   Tilg, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Crohn's disease; Cytokines; Intestinal inflammation; Regulatory T cells; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CHEMOKINE RECEPTOR CCR9; CORTICOSTEROID; DACLIZUMAB; FONTOLIZUMAB; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; METHOTREXATE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; OVALBUMIN; PLACEBO; RITUXIMAB; SECUKINUMAB; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB; CD3 ANTIBODY; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILL; CONFERENCE PAPER; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; FEVER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HELPER CELL; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; LEUKOCYTE MIGRATION; LIVER FUNCTION TEST; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REMISSION; STEROID REFRACTORY ULCERATIVE COLITIS; T LYMPHOCYTE; TH17 CELL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS; CELL HOMING; CLINICAL TRIAL (TOPIC); INFLAMMATORY BOWEL DISEASE; INTESTINE WALL; ANIMAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES;

EID: 84888217408     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000354687     Document Type: Conference Paper

References (65)

1. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, International IBDGC, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
2. Kaser A, Zeissig S, Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
3. Brandtzaeg P, Carlsen HS, Halstensen TS: The B-cell system in inflammatory bowel disease. Adv Exp Med Biol 2006; 579: 149-167.
4. Neurath MF, Meyer zum Buschenfelde KH: Transcription factors of T and B lymphocytes-basic research and clinical perspectives for gastroenterology. Z Gastroenterol 1996; 34: 138-150.
5. Fantini MC, Monteleone G, MacDonald TT: IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol 2008; 1: 110-115.
6. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS: The transcription factor T-bet regulates mucosal T-cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195: 1129-1143.
7. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M: CD4 + CD25 + T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173: 3119-3130.
8. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R: Peripheral and intestinal regulatory CD4 + CD25 high T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-1878.
9. Kobayashi K, Asakura H, Hamada Y, Hibi T, Watanabe M, Yoshida T, Watanabe N, Miura S, Aiso S, Tsuchiya M: T lymphocyte subpopulations and immunoglobulin-containing cells in the colonic mucosa of ulcerative colitis; a morphometric and immunohistochemical study. J Clin Lab Immunol 1988; 25: 63-68.
10. Ouyang W, Kolls JK, Zheng Y: The biological functions of T-helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
11. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin-17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
12. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93.
13. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W: Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198: 963-969.
14. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, Marquez G, Agace WW: CCL25 mediates the localization of recently activated CD8 + lymphocytes to the smallintestinal mucosa. J Clin Invest 2002; 110: 1113-1121.
15. Canva-Delcambre V, Jacquot S, Robinet E, Lemann M, Drouet C, Labalette M, Dessaint JP, Bengoufa D, Rabian C, Modigliani R, Wijdenes J, Revillard JP, Colombel JF: Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996; 10: 721-727.
16. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ: CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose-finding study. Gut 1997; 40: 320-327.
17. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J: A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007; 133: 1414-1422.
18. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ: Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010; 16: 620-629.
19. Guthery SL, Gross TG: Assessing the risk of Epstein-Barr virus-related lymphoproliferative disorders before administration of visilizumab. Gastroenterology 2008; 134: 895-896.
20. Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB: Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (hum291) in Crohn's disease. Am J Gastroenterol 2009; 104: 868-876.
21. Yu QT, Saruta M, Papadakis KA: Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol 2008; 127: 322-329.
22. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T: Fontolizumab, a humanised anti-interferon- antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1131-1137.
23. Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T: A dose-escalating, placebo-controlled, double-blind, single-dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon- antibody, in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1138-1144.
24. Reinisch W, de Villiers W, Bene L, Simon L, Racz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE: Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010; 16: 233-242.
25. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 369-376.
26. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS: Daclizumab, a humanised monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose-ranging trial. Gut 2006; 55: 1568-1574.
27. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 65-75.
28. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Gregus M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS: Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 2012; 143: 356-364. e351.
29. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin-12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290.
30. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
31. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG, Group CS: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528.
32. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczew ski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group: Secukinumab, a human anti-IL-17a monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-1700.
33. Tilg H, Kaser A: Vedolizumab, a humanized mAb against the 47 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs 2010; 11: 1295-1304.
34. Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, Kadambi VJ: Exclusive antagonism of the 47 integrin by vedolizumab confirms the gut selectivity of this pathway in primates. Inflamm Bowel Dis 2012; 18: 2107-2119.
35. Escorsell J: A report from the 20th United European Gastroenterology Week 2012 (October 20-24, 2012, Amsterdam, The Netherlands). Drugs Today (Barc) 2012; 48: 811-815.
36. Stefanich EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M: A humanized monoclonal antibody targeting the 7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011; 162: 1855-1870.
37. Keshav S, Vanasek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Racz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlen P, Schreiber S, Schall TJ, Bekker P; Prospective Randomized Oral-Therapy Evaluation in Crohn's Disease Trial P-SG: A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013; 8:e60094.
38. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
39. Ohkura N, Kitagawa Y, Sakaguchi S: Development and maintenance of regulatory T cells. Immunity 2013; 38: 414-423.
40. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742.
41. Veltkamp C, Anstaett M, Wahl K, Moller S, Gangl S, Bachmann O, Hardtke-Wolenski M, Langer F, Stremmel W, Manns MP, Schulze-Osthoff K, Bantel H: Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF- treatment. Gut 2011; 60: 1345-1353.
42. Hanai H, Iida T, Ikeya K, Abe J, Maruyama Y, Shimura T, Sugimoto K, Watanabe F: A new paradigm in ulcerative colitis: regulatory T cells are key factor which induces/exacerbates UC through an immune imbalance. Mol Immunol 2013; 54: 173-180.
43. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF: Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012; 143: 1207-1217.e1201-1202.
44. Engstrom JF, Arvanitakis C, Sagawa A, Abdou NI: Secretory immunoglobulin deficiency in a family with inflammatory bowel disease. Gastroenterology 1978; 74: 747-751.
45. MacDermott RP, Nash GS, Bertovich MJ, Mohrman RF, Kodner IJ, Delacroix DL, Vaerman JP: Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology 1986; 91: 379-385.
46. Ferreira RC, Pan-Hammarstrom Q, Graham RR, Gateva V, Fontan G, Lee AT, Ortmann W, Urcelay E, Fernandez-Arquero M, Nunez C, Jorgensen G, Ludviksson BR, Koskinen S, Haimila K, Clark HF, Klareskog L, Gregersen PK, Behrens TW, Hammarstrom L: Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat Genet 2010; 42: 777-780.
47. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365-375.
48. Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, Brown M, Triggs C, Chuang E, Princen F, Singh S: Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Inflamm Bowel Dis 2013; 19: 1139-1148.
49. Dotan I: New serologic markers for inflammatory bowel disease diagnosis. Dig Dis 2010; 28: 418-423.
50. Salinas GF, Braza F, Brouard S, Tak PP, Baeten D: The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol 2013; 146: 34-45.
51. Schmidt EG, Kristensen NN, Claesson MH, Pedersen AE: Enteroantigen- presenting B cells efficiently stimulate CD4 + T cells in vitro. Inflamm Bowel Dis 2011; 17: 308-318.
52. Defendenti C, Sarzi-Puttini P, Grosso S, Croce A, Senesi O, Saibeni S, Bollani S, Almasio PL, Bruno S, Atzeni F: B lymphocyte intestinal homing in inflammatory bowel disease. BMC Immunol 2011; 12: 71.
53. Olson TS, Bamias G, Naganuma M, Rivera-Nieves J, Burcin TL, Ross W, Morris MA, Pizarro TT, Ernst PB, Cominelli F, Ley K: Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 2004; 114: 389-398.
54. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125.
55. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciume G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP: BACH2 represses effector programs to stabilize T-mediated immune homeostasis. Nature 2013; 498: 506-510.
56. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N: Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012; 11:CD008079.
57. Furtado J, Isenberg DA: B-cell elimination in systemic lupus erythematosus. Clin Immunol 2013; 146: 90-103.
58. Coca A, Sanz I: Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012; 24: 451-456.
59. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D: Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791.
60. Danese S, Fiocchi C: Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725.
61. Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, Howarth D, Campbell F, Rhodes JM: Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011; 60: 1520-1526.
62. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF: Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13: 1365-1368.
63. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L: Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008; 57: 714-715.
64. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM: Severe ulcerative colitis after rituximab therapy. Pediatrics 2010; 126:e243-246.
65. Blombery P, Prince HM, Levinson M, Pianko S, Maxwell E, Bhathal P: Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2011; 29:e110-e112.